Actinium Pharmaceuticals (NYSE:ATNM) Receives Buy Rating from HC Wainwright

by · The Cerbat Gem

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 258.74% from the stock’s current price.

Several other research analysts have also recently issued reports on the stock. StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Stephens reissued an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Check Out Our Latest Research Report on ATNM

Actinium Pharmaceuticals Stock Performance

Shares of ATNM traded down $0.01 during trading hours on Tuesday, hitting $1.12. The company had a trading volume of 48,627 shares, compared to its average volume of 179,326. The stock has a market capitalization of $34.78 million, a price-to-earnings ratio of -0.80 and a beta of 0.10. The firm has a fifty day moving average price of $1.22 and a 200-day moving average price of $1.49. Actinium Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $10.24.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC bought a new position in Actinium Pharmaceuticals in the third quarter worth approximately $322,000. Wellington Management Group LLP purchased a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter worth $112,000. XTX Topco Ltd bought a new position in Actinium Pharmaceuticals in the 3rd quarter worth $268,000. Barclays PLC lifted its position in Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Actinium Pharmaceuticals by 3.0% during the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after purchasing an additional 19,843 shares in the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

(Get Free Report)

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).

See Also